This unit provides scientific information to support the decision making in healthcare policy and practice. Health Technology Assessment (HTA) Unit is a tool to ensure equity in the access to medicines and the most favourable benefit/risk and cost/effectiveness ratios in the drug use process.

HTA is, therefore, crucial in both drug reimbursement decisions at ambulatory settings and hospital formulary inclusion decision processes.

HTA provides Industry the following services:

• Definition of levels of scientific and clinical evidence according to literature evaluation
• Evaluation of comparative efficacy and effectiveness between relevant therapeutic options
• Pharmacoeconomic studies
• Production of expert reports on the assessment of risk/benefit and cost/effectiveness ratios

HTA is also responsible for the Pharmacovigilance Unit of the Centre Region (UFC) that is coordinated by the National Authority of Medicines and Health Products (INFARMED, IP).

Services

• Definition of levels of scientific and clinical evidence according to literature evaluation
• Evaluation of comparative efficacy and effectiveness between relevant therapeutic options
• Pharmacoeconomic studies
• Production of expert reports on the assessment of risk/benefit and cost/effectiveness ratios